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C-peptide is a small peptide connecting two chains of proinsulin molecule and is dissociated 
before the release of insulin. It is secreted in an equimolar amount to insulin from the pancreatic 
beta-cells into the circulation. Recent evidence demonstrates that it has other physiologic 
activities beyond its structural function. C-peptide modulates intracellular signaling pathways 
in various pathophysiologic states and, could potentially be a new therapeutic target for 
different disorders including diabetic complications. There is growing evidence that c-peptide 
has modulatory effects on the molecular mechanisms involved in the development of diabetic 
nephropathy. Although we have little direct evidence, pharmacological properties of c-peptide 
suggest that it can provide potent renoprotective effects especially, in a c-peptide deficient 
milieu as in type 1 diabetes mellitus. In this review, we describe possible molecular 
mechanisms by which c-peptide may improve renal efficiency in a diabetic milieu.  
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The prevalence of diabetes mellitus (DM) is growing exponentially worldwide [1]. It is now 
the more prevalent metabolic disorder with increasing incidence due to the adoption of a 
Western and sedentary life-style, especially among younger adults [2, 3]. This chronic disorder 
has a negative effect on all aspects of metabolism leading to the production of various toxic 
byproducts [3-6]. DM is responsible for various forms of tissue dysfunction known as diabetic 
complications [4, 5]. Diabetic nephropathy (DN) is one of the most important diabetes-induced 
complications which occur in an uncontrolled diabetic milieu and is considered as the primary 
cause of the end-stage renal disease (ESRD) [7, 8]. Emerging studies have studied the 
underlying molecular mechanisms of DN, however, its exact pathophysiology is still unclear 
[7, 9].   
The connecting or C-peptide (CP), is a short polypeptide consisting of 31 amino-acids that 
connects the A chain of proinsulin molecule to the B chain [10]. However, beyond the structural 
roles in the proinsulin molecules, some evidence suggests that CP can exert metabolic effects 
and hence may be considered as a potential new therapeutic target for diabetes as well as for 
various complications of diabetes [10-12]. The CP can bind to various types of cell surface 
receptors and modulate various intracellular signaling involved in the metabolic pathways and 
tissue function [10, 13]. Also, some evidence has implied that CP can suppress various 
molecular mechanisms involved in the pathophysiology of DN and thereby prevent the onset 
and progression of diabetes-induced renal failure [10, 14, 15]. In the current study, we have 
reviewed the potential renoprotective effects of CP.    
Classification of Diabetes Mellitus   
Type 1 diabetes (T1DM) and type 2 diabetes (T2DM)) are the two common forms of diabetes 
mellitus (DM) [16]. Type 1 diabetes (T1DM) accounts for about 5-10% of all patients with 
diabetes and mainly results from autoimmune destruction of beta-cells of the pancreas [16]. 
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Type 2 diabetes (T2DM) is the most prevalent type of diabetes, which accounts for about 90-
95% of patients with diabetes and is mainly due to inadequate response to insulin and insulin 
resistance in the peripheral tissues [16]. Gestational diabetes occurs in pregnant women due to 
hormonal variations in pregnancy and insulin resistance [17]. The maturity-onset diabetes of 
young, latent autoimmune diabetes in adults and secondary diabetes due to various medications 
such as corticosteroids or pathologies such as pancreatitis are some of the other forms of 
diabetes [16].  
Physiological properties of the C-Peptide  
CP was first discovered in 1967, when the insulin biosynthesis pathway was described by Givol 
[18]. CP has 31 amino-acids with C112H179N35O46 formula, a molecular weight of 3,020.29 
g/mol and a half-life of about 20-30 min and thereby, has more prolonged physiological activity 
compared to insulin which has a half-life of about 3-5 min [19, 20]. CP facilitates the assembly, 
folding and processing of the insulin peptide in the endoplasmic reticulum organelle. 
Equimolar amounts of CP and insulin are stored in the secretory granules of the pancreatic beta 
cells, which are both released in response to various stimuli into the circulation [18, 21]. Hence 
the circulating level of CP is closely related to the circulatory level of insulin [10, 11].  
 
Recent evidence has demonstrated that the CP is not an inert peptide with only structural 
functions, but also exerts some biological activities [20]. It has now shown that the CP can bind 
to some of the cellular membranes such as endothelial cells, pancreatic beta cells, renal tubular 
cells and fibroblasts; possibly via a specific type of G-protein dependent receptor (a pertussis 
toxin-sensitive one) and then activates a series of intracellular signaling pathways [20, 22]. 
This receptor is not sensitive to insulin or insulin-like growth factors (IGF-I and II), suggesting 
its specificity for CP [14, 23]. It has also been shown that CP can modulate nuclear events and 
gene transcription by binding to specific promoters and thereby has an effect on cell survival 
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[20, 24].  Moreover, CP has some degree of insulin-mimetic effects which enables it to 
modulate glucose metabolism and hyperglycemia as well as diabetes-related complications 
such as diabetic neuropathy and nephropathy [20-22]. While its plasma concentration is similar 
to that of insulin level in healthy subjects, CP is absent in T1DM, but exist in T2DM with 
varying concentrations depending on the stage and progression of DM [14]. The main 
recognized biological activities of CP are summarized in table 1.  
Physiologic Functions of C-Peptide Ref.  
Structural bridges between A and B chains of proinsulin molecule  [20] 
Stimulates Na+-K+-ATPase expression/activity   [25]  
Modulates eNOS and iNOS activities and thereby hemodynamic states  [20, 26] 
Induces intracellular signaling especially Ca2+-dependent pathways    [20, 26] 
Modulates gene transcription/expression   [20] 
Modulates glucose metabolism [20] 
Effects on cell survival  [10] 
Modulates thrombotic events   [27, 28]  
Modulates lipid metabolism  [29-31] 
Table 1; known physiological functions of c-peptide (eNOS=endothelial nitric oxide 
synthase, iNOS=inducible nitric oxide synthase)  
   
Pathophysiology of diabetic nephropathy at a glance  
Diabetic nephropathy (DN), which is the major cause of renal failure worldwide, has 
complicated and multi-factorial pathophysiology [32-34]. While many clinical studies have 
assessed its underlying causes, the exact pathophysiology of DN is remaining unclear [35-37]. 
However, activation of various molecular pathways such as oxidative stress [38], renin-
angiotensin system (RAS) [39], transforming growth factor-β (TGF-β) [40], protein kinase C 
(PKC) [39], tumor necrosis factor-α (TNF-α) [39], nuclear factor-kappa-b (NF-κB) [41], 
adhesion molecules up-regulation [42] and apoptotic events [38, 43] are closely related to 
different aspects of DN. Other pathophysiological mechanisms, such as hemodynamic 
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variations and intraglomerular hypertension, are responsible for a part of tissue injuries in 
kidneys during the development of DN [44][35, 37].  
C-Peptide and renal tissues; possible effects in diabetic nephropathy   
Studies have demonstrated that CP can modulate various intracellular signaling in kidneys [24]. 
A large number of intracellular mediators and pathways in renal tissues such as PKC (protein 
kinase c), ERK (extracellular-signal-regulated kinase), JNK (Janus kinase), TGF-β/Smad, 
iNOS, PPAR-γ and phosphoinositide 3-kinase are under the influence of the CP activity [45-
49]. CP can also exert direct regulatory effects on various elements of the nephrons, especially 
glomerulus and proximal tubule and thereby modulate renal function [14, 45, 50][14]. Evidence 
suggested that CP may provide renoprotective effects by ameliorating histological damages 
such as glomerular hypertrophy, mesangial expansion, tubulointerstitial inflammation, tubular 
sodium reabsorption and glomerular hyperfiltration leading to lowering of albuminuria [51-
55]. It may also suppress various apoptotic processes and tissue damages in renal tissues in the 
diabetic milieu [14, 56].  
Based on these observations, some evidence suggests that CP may be beneficial for the 
prevention of diabetes-induced pathophysiologic conditions such as DN, especially in patients 
with T1DM [14, 24, 55, 57]. Evidence demonstrates that patients with T1DM who have some 
functional pancreatic β-cells are substantially less susceptible to vascular complications than 
patients who lose their functional β-cell and thereby are CP deficient [58, 59]. In the following 
sections, we review the possible renoprotective effects of CP and discuss its therapeutic 
potential in the diabetic milieu for improvement in renal function and the prevention of DN.  
1. C-peptide and NF-κB 
NF-κB is an evolutionarily conserved protein from the Rel family which is widely expressed 
in most cell types and controls the expression of various genes involved in different cellular 
processes such as the inflammatory responses, cell development, cellular growth and cell 
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survival as well as responses to numerous stimuli such as free radicals, stress, cytokines, 
ultraviolet radiations and invader viral and bacterial antigens [60, 61]. NF-κB hyper-activation 
is commonly observed in most cases of DN and is responsible for various forms of renal injuries 
[60, 61]. This nuclear element is widely expressed in different segments of the renal tissues, 
especially in the cortical tubular, epithelial, glomerular and interstitial cells. It can up-regulate 
various factors involved in the pathophysiology of DN, such as inflammatory mediators, TGF-
β, Bcl2 and pro-oxidant enzymes and thereby, many studies have considered it as one of the 
primary therapeutic targets for DN [41, 60, 62, 63]. These studies have demonstrated that the 
modulation of NF-κB activity may ameliorate the onset and the progression of various 
deleterious pathways involved in DN [41, 60, 62].  
There is evidence suggesting that CP could potentially modulate NF-κB activity [64]. CP can 
regulate NF-κB activity in different tissues including the kidneys [24, 56, 64]. Cifarelli and 
coworkers in 2008 found that CP provides protective effects for vascular networks by inhibiting 
the NF-κB translocation and activity in the diabetic milieu [64]. Li et al. in 2018 demonstrated 
that CP could attenuate the progression of DN by inhibition of NF-κB activity and thereby its 
down-stream events [24]. Hills and coworkers in 2010 reported that modulation of NF-κB 
could ameliorate the renal damages in diabetes [56]. Al-Rasheed and colleagues in 2006 
demonstrated that the anti-apoptotic effects of CP are dependent on the NF-κB modulatory 
potentials in the renal tissues [65]. They suggested that CP-induced NF-κB activation protects 
the renal cells against the TNF-α–induced injury in the diabetic milieu [65]. Luppi and 
coworkers in 2008 have found that the CP therapy ameliorates the diabetes-induced endothelial 
dysfunction, which commonly occurs in DN [66]. This evidence suggested that CP replacement 
therapy may be beneficial against vascular disorders in patients with diabetes, especially TIDM 
[67]. Therefore, we can consider the modulatory effects on NF-κB as a possible molecular 
mechanism by which CP improves renal efficiency in the diabetic milieu [24, 56, 65-67].    
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2. Anti-Apoptotic Effects 
Apoptotic and fibrotic events have a pivotal role in the histological damages observed in DN 
[38, 43]. It has been shown that these deleterious processes are responsible for the diabetes-
induced histopathological injuries in various kidney tissues such as glomerulus and tubular 
cells and thereby, attenuating their progress is one of the main targets in the prevention and 
treatment of DN [38, 68]. There is strong evidence implying that CP can suppress these 
deleterious pathways and reduce the histological injuries in different tissues, especially in 
T1DM [56, 69, 70]. Li et al. in 2002 reported that CP reduced the Bax/Bcl-xl ratio and declined 
apoptosis in the hippocampal tissues of animals with T1DM [70]. Sima and coworkers in 2005 
found that CP therapy markedly reduces the apoptotic events and neuronal death in the 
hippocampal tissues and thereby improves cognitive function in T1DM [71]. Also, Al-Rasheed 
et al. in 2006 reported that CP attenuates DM-induced apoptosis in kidneys [65]. Cifarelli et al. 
in 2011 have shown that CP ameliorates the DM-induced apoptosis in endothelial cells by 
lowering RAC-1 (ras-related C3 botulinum toxin substrate 1) translocation to the membrane 
and by Nox activation in the human aortic endothelial cells [72].  Bhatt and coworkers in 2013 
provided further evidence suggesting that CP protects endothelial cells against DM-induced 
apoptosis and reduces tissue damages by a transamidation-dependent pathway [73]. In short, 
although most evidence has demonstrated the anti-apoptotic potentials of CP in the neuronal 
networks [70, 71], fewer studies indicated that it could exert the same effects in renal tissues 
and thereby prevent cellular death, especially in T1DM [65, 73]. However, more experimental 
studies are still needed to confirm this finding.   
3. Vasoprotective Effects 
DN can be considered as a vascular disorder with dysfunctional vessel walls, hemodynamic 
variations and lower efficiency of renal vascular networks [74, 75]. In this state, most renal 
vessels in glomerulus such as afferent and efferent arterioles are negatively affected by 
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hyperglycemia-induced pathophysiologic pathways and thereby loss of their normal 
physiologic functions [74, 75]. Therefore, some therapeutic targets for DN have been 
developed based on vasoprotective potentials [74, 76].  
There is evidence indicating that CP exerts potent vasoprotective effects in a diabetic milieu 
[69]. The earliest observation was by Johansson and coworkers in 1992, demonstrating that CP 
therapy increases the oxygen uptake and blood flow in muscles of patients with T1DM [77]. 
This evidence suggests that CP improves the vascular function of muscles in diabetic milieu 
[77]. Hansen and coworkers in 2002 have provided similar evidence in myocardial tissues 
indicating CP improves blood flow in the myocardium in patients with T1DM [78]. Further 
studies have confirmed these findings and suggested that CP-induced vasoprotective influences 
are related to the nitric oxide (NO) synthesis [79-83]. The CP potentially induces eNOS and 
iNOS activities and thereby increases NO bioavailability leading to an improved vascular tone 
and vascular efficiency [79, 81-83]. However, other possible pathways are also suggested [84]. 
Bhatt and coworkers in 2013 reported that CP-dependent vasoprotective potentials are partially 
related to the AMPKα (AMP-activated protein kinase α) pathways [84]. They observed that 
CP replacement therapy declined the AMPKα dephosphorylation in aortic vessels of diabetic 
animals [84]. Also, as mentioned earlier, CP attenuates the apoptotic events in endothelial cells, 
which provide further evidence on the vasoprotective potentials for this protein [73, 85]. These 
beneficial effects strongly suggest that CP therapy can provide a new therapeutic target against 
DM-induced vasculopathy as well as for DN [69].   
There is similar evidence in renal tissues [86, 87]. Kamikawa and colleagues in 2008 
demonstrated similar beneficial effects of CP in renal tissues [86]. They found that with one 
week of CP therapy in animals with T1DM significantly reversed the DM-dependent NO 
decline and improved the vascular function by inducing the eNOS activity in renal tissues and 
suggested that these effects may provide new renoprotective potentials [86]. This effect was 
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accompanied by higher eNOS expression in glomeruli and endothelial cells of renal arterioles 
of diabetic animals [86]. Panero et al. in 2009 conducted a large clinical study on patients with 
T1DM and found that fasting plasma CP level has a negative correlation with the incidence of 
vascular complications [59]. Elbassuoni et al., in recent research in 2018, demonstrated that 
CP prevents DN and improves renal function by NO-dependent mechanism [87]. They reported 
that CP replacement therapy might be a novel renoprotective therapy which works by NO 
synthesis induction and providing vasoprotective effects [87]. Although more studies are still 
needed, this evidence suggests that the CP can provide vasoprotective effects in the renal 
tissues [79, 81-83, 87].  
     
4. Anti-inflammatory effects  
Inflammatory responses have an essential role in the pathophysiology of DN [88, 89]. It has 
been shown that various pro-inflammatory mediators such as IL (interleukin)-1β, IL-6, IL-18, 
monocyte chemoattractant protein-1 (MCP-1), TNF-α , intercellular adhesion molecule 1 
(ICAM-1), vascular cell adhesion protein 1 (VCAM-1), E-selectin, different adiponectin, 
leptin, endothelial cell-selective adhesion molecule (ESAM) and matrix metalloproteinase-2 
(MMP-2) are closely associated to the onset and progression of DN [90-92]. Also, studies have 
suggested that different renal cells as glomerular, endothelial, tubular and mesangial cells 
express these pro-inflammatory cytokines and release them, which can result in structural and 
functional injuries in the kidneys [93, 94]. This evidence has led to the development of the 
inflammatory hypothesis, which emphasizes the significant role of inflammation in the 
pathophysiology of DN [90, 95].  
Emerging evidence indicates that CP has potent anti-inflammatory properties [96]. It can 
reduce the recruitment of leukocytes by down-regulation of different adhesion molecules such 
as p-selectin, ICAM-1 and VCAM-1, which are typically increased during the inflammatory 
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process [66, 96, 97]. Consequently, the expression and release of various inflammatory 
mediators are suppressed, leading to a lower local and systemic inflammation [96]. This effect 
may be via NF-κB inhibition in both endothelial cells and monocytes [98]. Haidet et al. in 2012 
found that CP suppresses the monocytes-dependent inflammatory responses by the inhibition 
of NF-κB and down-regulation of various inflammatory cytokines in T1DM [98]. CP is also 
capable of preventing the DM-induced vascular smooth muscle cell migration, which 
commonly occurs in diabetic vasculopathy [64, 99]. Moreover, some studies found a negative 
correlation between CP plasma concentration and the levels of circulating cytokines in patients 
with T1DM [100]. This pathway may provide new therapeutic targets against diabetes-induced 
vascular complications such as DN [58, 101, 102]. Chima and coworkers in 2011 have 
observed that CP improves renal function by attenuating the inflammatory responses in 
hemorrhagic shock [103]. They found that CP potentially down-regulates the c-Fos subunit, 
ERK 1/2 and JNK (c-Jun N-terminal kinase), leading to a lower expression of cytokines in the 
kidneys [103].  
However, some adverse reports are implying that CP exerts some inflammatory effects [54, 
104]. This evidence suggested that CP has proinflammatory roles in some conditions and 
thereby, induces inflammatory responses [54, 104]. For example, a recent study has reported 
that CP is correlated positively with the incidence of inflammatory nonalcoholic fatty liver 
disease (NAFLD) [105]. So, it seems that more experimental and clinical evaluations are still 




Figure 1: Possible links between C-peptide and renal function in the diabetic 
milieu  
 
5. Antioxidant Effects 
Oxidative stress is a major underlying cause of many complications resulting from DM [106, 
107]. This deleterious event occurs when the physiologic balance between free radicals and the 
antioxidant defense system deteriorates toward the production of more free radicals [106]. It 
has been shown that oxidative stress has a crucial role in various aspects of renal failure by 
inducing the pathophysiologic events leading to histological injuries [32]. The agents that can 
potentiate the antioxidative system have always tried for the prevention and treatment of 
various oxidative stress-dependent states, including DN [38].  
There is some evidence demonstrating the antioxidative properties of CP in different tissues 
[72, 84]. It has been demonstrated that CP potentiates the antioxidative system and protects 
various tissues against oxidative damages in a diabetic milieu [72, 84]. Ragy et al. in 2019 have 
shown that CP improved oxidative stress in the pancreatic tissues in TIDM [108]. Also, 
Cifarelli et al. in 2011 found that CP ameliorates the oxidative stress via lowering the Nox 
enzyme activity in the endothelial cells [72]. Moreover, Bhatt and coworkers in 2013 reported 
that CP reduces the free radical generation and provides antioxidative potentials by an AMPKα 
dependent mechanism [84]. 
Furthermore, Luppi et al. in 2014 demonstrated the antioxidant potency of CP in beta cells 
suggesting that CP can attenuate the oxidative stress in islets [109]. This evidence demonstrates 
the antioxidative capabilities of CP. Elbassuoni et al. in 2018 provided related evidence in the 
kidneys, indicating four weeks of CP therapy improved the renal function partially via lowering 
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the diabetic milieu 
[72, 109] [87] - 
Table 2; possible molecular interactions between c-peptide and diabetic 
nephropathy (DN=diabetic nephropathy, TGF-β= transforming growth factor-β, 
ICAM-1= intercellular adhesion molecule-1, VCAM-1= vascular cell adhesion 
molecule-1, TNF-α= tumor necrosis factor-α) 
Conclusion   
C-peptide is continuously released by the pancreatic β-cells along with insulin into the 
circulation and thereby is deficient in states with dysfunctional β-cells such as T1DM. It has 
now been accepted that the CP is not just an inert peptide with structural potency in the 
proinsulin molecule. CP is also a bioactive peptide with potent physiological functions with 
14 
 
modulatory effects on various intracellular signaling pathways and thereby provides a new 
therapeutic target for some of the diabetic complications, including DN. There is growing 
evidence that c-peptide has a protective potential through anti-oxidative, vasoprotective, anti-
apoptotic, anti-inflammatory and NF-κb modulatory effects, which enables it as a new target 
in the prevention and treatment of diabetic vasculopathy as well as diabetic nephropathy. 
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